Periodicidad semestral: flujo continuo.
ISSN - Electrónico: 2661-6947 / DOI: 10.36015 • LILACS BIREME (19784); LATINDEX (20666)
Introduction: breast cancer is the most frequent cancer in women; many efforts have been done to classify this cáncer based on genetic and immunohistochemical staining profile. Triple-negative breast cancer is defined by a lack of expression of estrogen and progesterone receptor as well as human epidermal growth factor receptor 2. It represents 15% of all types of breast cancer and arises more frequently in premenopausal Afro-American women. Objective: to establish the prevalence and describe the clinic pathologic features of patients with triple-negative breast cancer who were operated in the Obstetrics and Gynecology Ward of the HCAM in 2012. Materials and methods: this was a descriptive cross-sectional study in women with histologically confirmed breast cancer. We excluded patients whose paraffin blocks were not kept or were not able to perform all required immunohistochemical markers for the study. Results: a total of 159 cases of invasive breast cancer treated surgically in service in 2012, 17 were identified as triple negative tumors (ER negative, PR negative, HER-2 negative).
REFERENCIAS BIBLIOGRÁFICAS
American Cancer Society. Overview: Breast Cancer [internet]. 2006 [citado: 14 de octubre de 2012]. Disponible en: www.cancer.org
Ferlay J, Bray F, Pisan P, et al. International Agency for Research on Cancer. GLOBOCAN 2008. IARC. Cancer Database, No. 5, versión 2
Instituto Nacional de Cancerología (INC). Anuario Estadístico 2008. Bogotá: INC; 2009
Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature, 2000; 406:747-52
Van’t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-6
Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492-502
Van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol. 2002;161:1991-6
Rakha EA, Tan DS, Foulkes WD, et al. Are triple-negative tumours and basal-like breast cancer synonymous? Breast Cancer Res. 2007;9:404
Moll R, Krepler R, Franke polypeptide patterns observed i WW. Complex cytokeratin n certain human carcinomas. Differentiation. 1983;23:256-69
Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264-71
Bosch A, Eroles P, Zaragoza R, et al. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev. 2010;36:206-15
Wellings SR, Roberts P. Electron microscopy of sclerosing adenosis and infiltrating duct carcinoma of the human mammary gland. J Natl Cancer Inst. 1963;30:269-87
Sarkar K, Kallenbach E. Myoepithelial cells in carcinoma of human breast. Am J Pathol. 1966;49:301-7
Murad TM, Scharpelli DG. The ultrastructure of medullary and scirrhous mammary duct carcinoma. Am J Pathol. 1967;50:335-60
Dairkee SH, Mayall BH, Smith Hs, et al. Monoclonal marker that predicts early recurrence of breast cancer. Lancet. 1987;1:514
Malzahn K, Mitze M, Thoenes M, et al. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch. 1998;433:119-29
Fulford LG, Easton DF, Reis Filho JS, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology. 2006;49:22-34
Rodríguez S, Sarrio D, Honrado E, et al, Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinoma. Clin Cancer Res. 2006;12:1533-9
Liedtke C, Mazouni CH, Kenneth RH, et al. Response to Neoadjuvant theraphy and long-term survival in patients with triple-negative. Breast Cancer JCO. 2008;26:1275-81
Lara Medina F, Pérez Sánchez V, Saavedra Pérez D, et al. Triple- negative breast cancer in hispanic patients: High prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer. 2011;117:3658-69
Vallejos CS, Gómez HL, Cruz WR, et al. Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database. Clinical Breast Cancer. 2010;10:294-300
De Brot M, Soares FA, Stiepcich M, et al. Basal like breast cancers: clinicopathological features and outcome. Rev Assoc Med Bras. 2009;55:529-34
The authors who publish in this journal accept the following conditions:
1. The authors retain the copyright and grant to the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM the right of the first publication, with the work registered with the Creative Commons attribution license, which allows third parties to use the published material provided that they mention the authorship of the work and the first publication in this journal.
2. Authors can make other independent and additional contractual agreements for the non-exclusive distribution of the version of the article published in this journal (for example, include it in an institutional repository or publish it in a book) as long as it clearly indicates that the work was published. for the first time in the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM.